<DOC>
	<DOCNO>NCT00368368</DOCNO>
	<brief_summary>This study investigate effect renal impairment pharmacokinetics/pharmacodynamics GK Activator ( 2 ) patient type 2 diabetes , evaluate effect renal function safety drug . Patients assign treatment group accord renal function ( normal , moderate renal impairment , severe renal impairment ) . After 1 week washout period current oral anti-diabetic treatment , patient receive single oral dose 100mg GK Activator ( 2 ) , blood urine sample take 96h post-dose . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Effect Renal Impairment Activity GK Activator ( 2 ) Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes , take current sulfonylureas and/or metformin therapy &gt; =1 week prior dose GK Activator ( 2 ) ; normal renal function , moderate severe impairment . type 1 diabetes ; treatment insulin PPAR gamma agonist within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>